Saturday 17 October 2026
Export CRVO’s income statement to Excel — free account
CervoMed Inc.
CRVO Healthcare Biotechnology
CervoMed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, down 58.9% from fiscal 2024. In the quarter to June 2026, revenue fell 99.6%, EPS grew 8.57% and free cash flow fell 6.20%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.24
0.01
−0.44%
Follow CRVO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 2 | 2 |
+8 more TTM periods Free account |
| (107.62%) | (132.76%) | (93.92%) | (71.42%) | ||
| (94.73%) | (111.89%) | (81.76%) | (64.37%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(132.18%) | (282.94%) | (147.98%) | (98.36%) | |
Average Days of Receivables |
— | — | 38.90 | 80.67 | |
Free Cash Flow per Share |
(2.73) | (2.98) | (2.59) | (2.69) | |
Free Cash Flow |
(27.98) | (27.57) | (23.45) | (24.93) | |
| Other line items | |||||
Cash ROIC |
(58.41%) | (117.14%) | (59.99%) | (46.76%) | |
Accounts Receivable Turnover |
— | — | 2.99 | 7.58 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 544.54% | 374.58% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 261.68% | 167.06% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 36.16% | 24.15% | |
Operating CF/Net income |
0.92 | 0.92 | 0.87 | 0.97 | |
Revenue per Share |
0.00 | 0.00 | 0.44 | 0.67 | |
Operating CF per Share |
(2.73) | (2.98) | (2.59) | (2.69) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates